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Abstract
AIM
To identify significant liver disease [including nodular 
regenerative hyperplasia (NRH)] in asymptomatic Dida-
nosine (DDI) exposed human immunodeficiency virus 
(HIV) positive patients.
METHODS
Patients without known liver disease and with > 6 mo 
previous DDI use had liver stiffness assessed by transient 
elastography (TE). Those with alanine transaminase 
(ALT) above upper limit normal and/or TE > 7.65 kPa 
underwent ultrasound scan (U/S). Patients with: (1) 
abnormal U/S; or (2) elevated ALT plus TE > 7.65 kPa; 
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or (3) TE > 9.4 kPa were offered trans-jugular liver 
biopsy (TJLB) with hepatic venous pressure gradient 
(HVPG) assessment.
RESULTS
Ninety-nine patients were recruited, median age 50 
years (range 31-70), 81% male and 70% men who have 
sex with men. Ninety-five percent with VL < 50 copies 
on antiretroviral therapy with median CD4 count 639 IU/L. 
Median DDI exposure was 3.4 years (range 0.5-14.6). 
Eighty-one had a valid TE readings (interquartile range/
score ratio < 0.3): 71 (88%) < 7.65 kPa, 6 (7%) 
7.65-9.4 kPa and 4 (6%) > 9.4 kPa. Seventeen (17%) 
met criteria for TJLB, of whom 12 accepted. All had 
HVPG < 6 mmHg. Commonest histological findings were 
steatosis (n  = 6), normal architecture (n  = 4) and NRH 
(n  = 2), giving a prevalence of previously undiagnosed 
NRH of 2% (95%CI: 0.55%, 7.0%).
CONCLUSION
A screening strategy based on TE, liver enzymes and 
U/S scan found a low prevalence of previously undia-
gnosed NRH in DDI exposed, asymptomatic HIV positive 
patients. Patients were more likely to have steatosis 
highlighting the increased risk of multifactorial liver disease 
in this population.
Key words: Nodular regenerative hyperplasia; Human 
immunodeficiency virus; Steatosis; Non-cirrhotic portal 
hypertension; Didanosine
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Human immunodeficiency virus positive pa-
tients are at increased risk of liver disease. The aetio-
logy is often multifactorial and includes exposure to 
antiretroviral therapy. We used a simple screening stra-
tegy based on transient elastography, liver enzymes and 
ultrasound scan to identify that 2% of asymptomatic 
patients exposed to Didanosine in a clinical cohort had 
undiagnosed nodular regenerative hyperplasia. A further 
6% had undiagnosed steatosis. Implementation of a 
screening strategy enables identification of liver disease 
and initiation of earlier targeted interventions in this 
high-risk group.
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2016; 8(36): 1623-1628  Available from: URL: http://www.
wjgnet.com/1948-5182/full/v8/i36/1623.htm  DOI: http://dx.doi.
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INTRODUCTION
Nodular regenerative hyperplasia (NRH) - the develop-
ment of micronodules in liver parenchyma without 
intervening fibrosis[1] - has been reported in human 
immunodeficiency virus (HIV) positive patients who 
often present late in the course of the condition with 
complications associated with non-cirrhotic portal hyper-
tension (NCPH). A strong association with NRH is current 
or previous use of Didanosine (DDI)[1-6]. Although DDI is 
no longer used as first line antiretroviral therapy (ART), 
many HIV positive patients have significant previous 
exposure with a reported prevalence of NRH of between 
0.5%-35%[1,2,6]. This wide range is indicative of the 
unreliability of screening strategies and the fact that 
studies largely included individuals diagnosed with NRH 
or NCPH as a result of liver biopsy for other conditions 
or as a result of late presentation with complications of 
portal hypertension[1-6]. However prior to this the disease 
is largely sub clinical and a screening strategy may 
be useful to identify patients with DDI associated liver 
disease earlier in the disease process. 
Other studies have reported raised transaminases in 
NRH, but in many cases transaminases are only mildly 
elevated or not at all this indicating the unreliability 
of this alone as a screening tool[1]. Hepatic transient 
elastography (TE) is a validated non-invasive tool with 
good correlation for identifying hepatic and peri-portal 
fibrosis[2,7]. TE is also associated with hepatic venous 
pressure gradients (HVPG) in cirrhosis[8]. The co-relation 
with NRH is less well delineated, however increased liver 
stiffness readings have been reported in patients with 
both NRH and NCPH[9-14], although one study found that 
liver stiffness readings did not predict the presence of 
portal hypertension in NRH[10]. Many studies also report 
reduced platelet levels and the presence of splenomegaly 
in individuals with NRH[1].
Our aim was to develop and implement a screening 
strategy incorporating 3 separate measures; TE, platelet 
and alanine transaminase (ALT) levels, with subsequent 
ultrasound and trans-jugular liver biopsy (TJLB) in those 
who met criteria to identify DDI related liver disease 
in HIV positive patients with previous significant DDI 
exposure, but who were currently asymptomatic. 
MATERIALS AND METHODS
This study is a cross-sectional study in HIV outpatients 
at The Royal Free London NHS Foundation Trust from 
2010 to 2011. Ethical approval was obtained (REC 10 
/H0720/54). Study subjects were identified from the 
HIV clinical database. HIV positive patients currently 
under active follow-up and previously exposed to DDI 
therapy for longer than 6 mo were eligible to take part. 
Exclusions were viral hepatitis co-infection, age < 18 
years, a body mass index (BMI) > 40, pregnancy or 
ascites. Patients were sequentially recruited as they 
attended for routine clinic follow-up. Statistical review of 
the study was performed by a biomedical statistician (Dr. 
Colette Smith).
Patients completed a study specific questionnaire 
on sociodemographic factors, medical history, lifestyle 
1625 December 28, 2016|Volume 8|Issue 36|WJH|www.wjgnet.com
including smoking, alcohol [Michigan Alcoholism Screen-
ing test (MAST)] and drug use. Clinical data (HIV viral 
load, CD4 count, whether on/off treatment, date of 
diagnosis, date of ART start, lipids, liver panel bloods, 
blood glucose, BMI) were also collected. 
Liver TE was measured using FibroScan (FS) (Echosens, 
Paris). A median stiffness reading was measured using 
at least ten readings with a valid reading recording 
60% accuracy and an interquartile range (IQR) of less 
than 30% of the median. Subjects were offered further 
evaluation with ultrasound of liver and spleen with dop-
pler waveforms of the hepatic vasculature if they had 
either: (1) an ALT level above 19 IU/mL for women and 
31 IU/mL for men; or (2) a platelet count (PLT) less than 
120 × 109/L; or (3) TE reading of > 7.65 kPa (IQR < 0.3).
Individuals with evidence on ultrasound of spleno-
megaly or fatty liver or coarse echotexture or abnorma-
lities of hepatic doppler waveforms in conjunction with a 
raised ALT or TE reading as above were offered a TJLB 
with HVPG measurements. Patients with a raised ALT or 
platelets < 120 × 109/L for whom an elastography score 
was unobtainable (centripetal obesity) or uninterpretable 
(less than 10 valid readings or IQR/LSM > 30%) were 
offered ultrasound and TJLB.
All TJLB procedures were performed in the inter-
ventional radiology suite by an experienced operator 
(O’Beirne J) after a 6-h fast, under local anaesthesia. 
Biopsies were taken using a 19G Tru-cut type biopsy 
needle (Quick core; Cook, William Cook Europe, 
Denmark). Three or 4 passes were performed through 
the same hepatic vein wall (right or middle) to ensure 
that sufficient liver tissue was obtained. Wedge hepatic 
vein pressures (WHVP) were measured using a 5-F 
Berenstein balloon catheter (Boston Scientific, Natick, 
MA) using the technique described by Groszmann and 
Wongcharatrawee[15]. Three sets of measurements were 
taken. WHVP was measured for at least 1 min each time. 
HVPG was calculated as the mean of the 3 gradients (the 
difference between WHVP minus free hepatic pressure). 
Groups were compared using the Mann Whitney U test 
for non-parametric continuous variables and using the χ2 
test for categorical variables.
RESULTS
Four hundred and fifty-nine patients exposed to DDI for 
longer than 6 mo were identified from the clinic data-
base. Eighty-four patients known to have co-infection 
with hepatitis B or C were excluded. No patients were 
excluded due to BMI > 40 or presence of ascites. Of 
the remaining 376 patients, 99 patients were recruited 
sequentially as they attended HIV clinic during the study 
time period and response rates in those approached to 
take part in the study were > 95%. 
Characteristics of patients recruited (n = 99) were 
compared to those not approached to take part (n = 
274) to assess potential for recruitment bias. There were 
no differences in those recruited by sex: 80.8% (80/99 
recruited) vs 78.5% (215/274) not recruited were 
male; P = 0.41, total length of DDI exposure (mean 4.1 
years recruited vs 4.1 years not recruited; P = 0.89), 
most recent median ALT (34 μ/L recruited vs 35 μ/L not 
recruited; P = 0.85) or most recent median platelets 
(210 recruited vs 210 not recruited; P = 0.09). However 
a larger proportion of those of white ethnicity were 
recruited (77% vs 64% P = 0.02) and of those they had 
a slightly older mean age (50 years vs 48 years; P = 
0.001). 
Of the 99 who took part in the study, 75 (75%) 
were men who have sex with men (MSM). Mean age 
was 50 years (range: 30 to 70), 76% were White, 19% 
Black and 5% were of another ethnicity. The majority 
had well-controlled HIV infection with a median CD4 
count of 637 mm3 (IQR: 254 to 1378) and 92% had a 
suppressed HIV VL at < 40 copies. All were on ART and 
had been for a median of 15 years (IQR: 13 to 16 years). 
None were currently on a DDI containing ART regime. 
Median cumulative time previously on DDI was 43 mo 
(IQR: 22 mo to 68 mo). Overall, 43 (43%) patients 
reported never drinking alcohol or consuming less than 
2 units monthly. Only 2 patients scored > 6 on the MAST 
score indicating hazardous drinking. 
The screening algorithm is shown in Figure 1. ALT 
above the upper limit normal (ULN) (19 IU/mL in women 
and 31 IU/mL in men) was found in 37% (n = 7/19) of 
women and 50% of men (n = 40/80). Median ALT in 
men was 32 μ/L (IQR 23-44) and 18 μ/L in women (IQR 
15-22). Eight-two (82%) had a valid TE reading (IQR/
score ratio < 0.3 and success rate > 60%). Of these, 73 
(73%) were < 7.65 kPa, 5 (6%) between 7.65-9.4 kPa 
and 4 (4%) > 9.4 kPa (Figure 1). Only one subject had 
platelets < 120 and they were known to have cirrhosis of 
the liver at study entry. 
Ultrasound assessment was offered to 49 patients 
(49%) based on TE reading and/or ALT result. All those 
that met the criteria for ultrasound were screened for 
autoimmune liver disease and thrombophilia with a coagu-
lation screen. Four patients did not attend for ultrasound. 
The most common abnormality was increased reflectivity 
indicating fatty filtration in 8 patients (18%). A further 4 
patients had a normal liver ultrasound but were offered a 
TJLB on the basis of their ALT and TE score. In total 17 met 
criteria for TJLB of whom 12 accepted. The characteristics 
of these patients are described in Table 1. There were no 
complications observed from the TJB procedures. In the 
5 who did not accept liver biopsy, ultrasound appearances 
were normal in 2 subjects, indicative of fatty infiltration of 
the liver in 2 and demonstrated splenomegaly in one. Two 
had abnormal FS readings > 7.76 kPa.
Overall, the commonest histological finding on liver 
biopsy was steatosis (n = 5) or normal architecture 
(n = 4). All subjects had HVPG < 6 mmHg (n = 11) 
including the 2 patients with previously undiagnosed NRH 
on biopsy in-keeping with a pre-sinusoidal component. 
This gives a prevalence of previously undiagnosed NRH 
in our cohort of 2% (95%CI: 0.55%, 6.8%).
As a sensitivity analyses we applied our study algo-
rithm to two other patients attending the HIV clinic 
with previously identified DDI related liver disease. One 
Logan S et al . Liver disease in HIV patients on Didanosine
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case had been identified due to complications of portal 
hypertension and the other from liver biopsy undertaken 
due to abnormal ultrasound scan (U/S) appearances. 
Both cases met our study screening criteria to proceed to 
TJLB indicating they would have been detected using our 
screening process. 
DISCUSSION
NRH largely presents with complications associated with 
NCPH after a prolonged asymptomatic period[1-6,9,12]. 
Although the aetiology may be multi-factorial, an over-
riding association is use of DDI. A recent study also 
identified an association between single-nucleotide poly-
morphisms in the 5’-nucleotidase and xanthine oxidase 
genes and development of NCPH after DDI exposure[13] 
suggesting an element of genetic predisposition via the 
purine metabolism pathway.
Our study is the first to use a screening strategy to 
identify asymptomatic individuals with a previous DDI 
exposure but with no known liver disease at study entry. 
Such a strategy is important to identify liver disease 
at an earlier stage so that preventative measures and 
risk minimisation strategies may be instituted. Using 
our screening strategy we found 2 cases of previously 
undiagnosed NRH, but no cases of NCPH. Our strategy 
was based on TE, platelets and ALT levels, with ultrasound 
and subsequent TJLB in those who met criteria. We used 
a combination of methods to improve sensitivity of the 
screening strategy. Elevated transaminases, low platelets 
and moderate elevations in TE readings have all been 
described in known cases of NRH or NCPH. We chose a 
low TE cut off of 7.65 kPa as one study reported a median 
FS value of 7.9 kPa in subjects with biopsy confirmed 
NRH[10]. In addition in order to identify individuals with very 
low-level transaminase elevations we used a ULN cut off 
of 19 IU/mL in women and 31 IU/mL in men, contrasting 
with the ULN of 41 μL/L used in previous studies[2]. 
A recent multi-centre cohort of DDI-associated NCPH 
in HIV-infected adults identified thrombocytopenia, sple-
nomegaly and elevated aminotransferases and alkaline 
phosphatase as significantly associated with NCPH[14]. 
The authors suggest a screening algorithm for NCPH 
consisting of DDI exposure or splenomegaly plus either 
HIV positive and exposed to 
DDI for > 6 mo (n  = 459)
Sampling frame 
(n  = 376)
Recruited sequentially in clinic (n  = 99)
TE < 7.65 kPa
(n  = 73)
TE: 7.65-9.4 kPa
(n  = 5)
TE > 9.4 kPa
(n  = 4)
Unobtainable or invalid reading 
IQR/score > 0.3 (n  = 17)
HBV/HCV co-infection 
(84) or known DDI 
related liver disease 
(n  = 2) excluded
ALT < ULN
(n  = 44)
ALT > ULN 
(n  = 29)
Ultrasound offered
(n  = 49)
ALT > ULN
(n  = 11)
ALT < ULN
(n  = 6)
Normal ultrasound
(n  = 32)
Abnormal ultrasound 
(n  = 13)
Did not attend
(n  = 4)
n  = 282 n  = 4
1
No further follow-up 
(n  = 72)
Biopsy offered 
(n  = 17) No further follow-up 
(n  = 6)
Normal liver 
architecture 
(n  = 4)
Steatosis 
and/or fibrosis
(n  = 6)
Nodular 
regenerative 
hyperplasia (n  = 2)
Refused biopsy 
(n  = 5)
Figure 1  Screening algorithm to detect Didanosine related liver disease in human immunodeficiency virus positive patients previously exposed to 
Didanosine for > 6 mo. 1ALT > upper limit normal (ULN) or platelets < lower limit normal (LLN) or TE > 7.65 kPa; 2ALT < ULN and platelets > LLN and TE < 7.65 kPa. 
TE: Transient elastography; HIV: Human immunodeficiency virus; DDI: Didanosine; ALT: Alanine transaminase; HBV: Hepatitis B virus; HCV: Hepatitis C virus; IQR: 
Interquartile range.
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a raised serum aminotransferase or thrombocytopenia 
or raised alkaline phosphatase as a trigger for further 
assessment. Using this study’s algorithm only one third of 
our cohort would have been offered further investigation 
and one of the two cases of NRH identified in this study 
prior to development of NCPH would have been missed. 
Furthermore, splenomegaly is not uncommon in HIV 
positive patients[16].
We opted to use TE together with ALT and platelet 
counts on the basis of ready availability of blood tests 
and the ease of use of FS in the outpatient ambulatory 
setting. The most common histological abnormality we 
found on liver biopsy was steatosis, in association with 
fibrosis in 2 cases. We are unlikely to have missed cases 
though cannot exclude NRH in those who declined biopsy, 
but is unlikely that they had underlying NRH in a greater 
frequency that that seen in patients who did agree to 
undergo biopsy. Whilst DDI-associated NRH and NCPH 
is a serious condition with potentially life-threatening 
complications, this prospective study suggests a relatively 
low prevalence in treated cohorts. A previous study has 
identified non-alcoholic steatohepatitis (NAFLD) as a 
significant cause of unexplained serum aminotransferase 
elevation[12] in HIV positive people on ART and we 
also showed a significant rate of hepatic steatosis in 
association with hepatic fibrosis in our patients.
In this cross sectional study, we found a low pre-
valence of previously undiagnosed DDI-associated NRH 
using a screening strategy that combines TE, serum 
aminotransferase and platelet measurements followed 
by an U/S. We did, however, demonstrate a higher pre-
valence of NAFLD, which requires active management to 
address risk factors and prevent progression to fibrosis in 
HIV-positive patients.
Subject 
number
Gender Age 
(yr)
Ethnicity Prior DDI 
exposure 
(mo)
Time 
since 
DDI (yr)
BMI 
(kg/m2)
MAST 
score
ALT 
(IU/mL)
PLTs 
(106/L)
PTT Alk 
Phos 
(U/L)
FS 
(kPa)
Ultrasound 
results
Biopsy results HVPG Fib 4 
Participants who accepted to undergo TJLB as a result of study screening
   1 Male 43 White 
British
  81   7 25.58 0   77 175 14.0   83 10 Splenomegaly NRH with 
mild steatosis
5 1.29
   2 Male 59 White 
British
  40   6 24.42 0   36 175 14.8   93   8 Normal NRH 4 2.39
   3 Male 48 White 
British
    9   6 29.76 0   32 184 14.3 108 NR Fatty liver, 
Splenomegaly
Moderate 
steatosis
3 1.08
   4 Male 52 White 
British
  70   7 24.69 0   50 242 11.7   44      5.6 Fatty liver Mild steatosis 3 0.79
   5 Male 49 White 
Other
  34   4 28.54 1   60 215 14.0   83    12.6 Fatty liver Moderate 
steatosis, 
moderate 
fibrosis
3 1.38
   6 Male 52 White 
British
  21 11 28.67 1   58 257 13.4   43 NR Fatty liver Moderate 
steatosis
Not 
done
1.02
   7 Male 62 White 
Other
  13 13 32.56 2   56 175 11.1   45 NR Fatty liver Moderate 
steatosis
2 2.25
   8 Male 50 White 
British
117   3 31.18 0 125 204 10.7   58      8.7 Fatty liver Mild fibrosis 
with mild 
steatosis 
2 1.71
   9 Female 56 Black 
African
  24 11 36.96 0   27 208 12.3   67      4.4 Coarse 
echotexture
Normal 
Architecture
5 1.07
   10 Male 57 White 
British
  61   4 0   40 190 13.9   71 NR Splenomegaly Normal 
Architecture
3 1.74
   11 Male 51 White 
Irish
103   4 20.30 0   56 228 10.8 154      4.8 Coarse 
echotexture
Normal 
Architecture
3 1.04
   12 Male 52 White 
Other
  44   5 21.07 6   24 224 11.4   62      9.1 Normal Normal 
Architecture
2 1.16
Participants who refused TJLB offered as a result of study screening
   13 Male 46 White 
British
  74   2 21.46 0   18 177   60 10 Normal Declined 1.41
   14 Male 41 White 
British
  97   3 25.65 0   63 188 101      7.6 Splenomegaly Declined 1.30
   15 Male 47 White 
British
  33   5 24.39 0   34 238   58      7.1 Fatty liver, 
dampened 
waveform
Declined 0.99
   16 Male 61 White 
British
110   2 20.75 1   35 246 71      9.2 Normal Declined 1.39
   17 Male 54 White 
British
 28   5 28.93 1   32 333 58      4.3 Fatty liver Declined 0.67
Table 1  Characteristics of those with liver disease identified as a result of study screening
DDI: Didanosine; BMI: Body mass index; MAST: Michigan Alcoholism Screening test; ALT: Alanine transaminase; PLT: Platelet count; FS: FibroScan; TJLB: 
Trans-jugular liver biopsy.
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COMMENTS
Background
Human immunodeficiency virus positive patients are at increased risk of liver 
disease. This is multifactorial and includes co-infection with hepatitis viruses, 
prescribed and recreational drug use and alcohol. The anti-retroviral drug 
Didanosine (DDI) has been implicated in the aetiology in some patients, 
particularly if the type of liver damage is nodular regenerative hyperplasia (NRH) 
or a patient has non-cirrhotic portal hypertension.
Research frontiers
The authors used a combination of liver enzyme level (with a lower upper limit 
of normal) and transient elastography (TE) (which measures the liver stiffness) 
as an initial screen of patients exposed to DDI. This highly sensitive approach 
identified 42% who required further investigation with an ultrasound scan and 
17% who subsequently were offered a transjugular liver biopsy. The authors, 
therefore, believe that the prevalence rate of 2% NRH in this DDI exposed 
asymptomatic cohort is accurate.
Innovations and breakthroughs
The prevalence study is the first to systematically screen asymptomatic patients 
exposed to DDI. Other groups have looked at the association between the 
drug and liver disease but have not screened a large cohort of exposed but 
asymptomatic patients to establish a prevalence of disease.
Applications
Use of a simple screening strategy in patients previously exposed to DDI will 
allow clinicians to identify liver disease which if left undiagnosed may present 
with the complications of portal hypertension such as variceal bleeding.
Terminology
TE: A technique combining ultrasound waves and a pressure transducer to 
assess the stiffness of the liver. This has been validated as a tool to measure 
liver fibrosis and steatosis; NRH is characterized by small (less than 3 mm) 
regenerative nodules in the absence of fibrous septa on biopsy. The nodules 
cause obliteration of the portal veins which leads to portal hypertension.
Peer-review
It is an interesting study.
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